COVID-19 and the Editorial Process: Reflections from The Journal of Pediatrics.
Welch, TR; Long, SS; Madan, RP; McDevit, M; Balistreri, WF.
The Journal of Pediatrics.
2020;
224:4-5.
Introducing Jorge A. Bezerra, M.D., Our 2020 AASLD President.
Balistreri, WF.
Hepatology.
2020;
72:801-806.
Natural Course of Pediatric Portal Hypertension.
Kassam, A; Goddard, GR; Johnston, ME; Cortez, AR; Trout, AT; Jenkins, TM; Miethke, AG; Campbell, KM; Bezerra, JA; Balistreri, WF; et al.
Hepatology Communications.
2020;
4:1346-1352.
Treatment of Hepatitis C: A New Paradigm toward Viral Eradication.
Squires, JE; Balistreri, WF.
The Journal of Pediatrics.
2020;
221:12-U65.
Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
Schwarz, KB; Rosenthal, P; Murray, KF; Honegger, JR; Hardikar, W; Hague, R; Mittal, N; Massetto, B; Brainard, DM; Hsueh, C; et al.
Hepatology.
2020;
71:422-430.
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to < 12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
Rosenthal, P; Schwarz, KB; Gonzalez-Peralta, RP; Lin, C; Kelly, DA; Nightingale, S; Balistreri, WF; Bansal, S; Jonas, MM; Massetto, B; et al.
Hepatology.
2020;
71:31-43.
The Journal of Pediatrics-Goals and Successes.
Balistreri, WF; McDevitt, M.
The Journal of Pediatrics.
2019;
212:4-5.
Fatal Neonatal Hepatic Steatosis: A New Familial Disorder.
Khan, S; Balistreri, W.
The Journal of Pediatrics.
2019;
210:145-145.
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Murray, KF; Balistreri, WF; Bansal, S; Whitworth, S; Evans, HM; Gonzalez-Peralta, RP; Wen, J; Massetto, B; Kersey, K; Shao, J; et al.
Hepatology.
2018;
68:2158-2166.
Enhancing the Development and Retention of Physician-Scientists in Academic Pediatrics: Strategies for Success.
Alvira, CM; Steinhorn, RH; Balistreri, WF; Fineman, JR; Oishi, PE; Padbury, JF; Kinsella, JP; Abman, SH.
The Journal of Pediatrics.
2018;
200:277-284.